ALPHAMAB-B (09966) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

HK Stock MarketDetailed Quotes

09966 ALPHAMAB-B

Watchlist

3.930
-0.060-1.50%

Not Open Feb 17 16:08 CST

3.78BMarket Cap-15.98P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Revenues Tell The Story For Alphamab Oncology (HKG:9966) As Its Stock Soars 25%
Simply Wall StFeb 16 19:36 ET
Alphamab Oncology (HKG:9966): Is Breakeven Near?
Simply Wall StFeb 10 22:51 ET
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
wallstreetcnFeb 7 20:59 ET
Hong Kong stocks movement | ALPHAMAB-B (09966) rose over 4% as its differentiated pipeline layout gradually enters a harvest period. Institutions are bullish on its long-term development.
ALPHAMAB-B (09966) rose over 4%, as of the time of writing, it increased by 4.08%, priced at 3.57 Hong Kong dollars, with a transaction volume of 18.34 million Hong Kong dollars.
Zhitong FinanceJan 3 02:24 ET
Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval From CDE to Initiate a Phase III Clinical Study for Ovarian Cancer
Yahoo FinanceDec 30, 2024 00:28 ET
Express News | Alphamab Oncology - Approval From Cde China for Jskn003 to Initiate a Phase III- Clinical Study for Treatment of Oc
ReutersDec 26, 2024 23:01 ET

Comments

Moomoo AI

Feb 7, 2024 00:43

Alphamab Oncology's high P/S ratio may not be justified due to weak revenue forecasts. Investors should remain cautious as this could negatively impact the share price.

Alphamab Oncology's (HKG:9966) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Spinee

Jan 17, 2024 02:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

Moomoo AI

Dec 22, 2023 20:10

Due to Alphamab Oncology's slower growth rate compared to the industry and notably high P/S ratio, investors may face potential risks. The company's elevated stock price level may not be sustainable in light of its comparatively weak revenue outlook.

What Alphamab Oncology's (HKG:9966) P/S Is Not Telling You

Flord

Sep 24, 2021 05:26

$ALPHAMAB-B (09966.HK)$ If corning & Jerry's late-stage data can validate the early-stage data, it means that first-line treatment of NSCLC(MOS estimated at more than 25 months in phase II) can obtain MOS data much higher than K

Mikebierer

Sep 24, 2021 05:13

$ALPHAMAB-B (09966.HK)$ $KINTOR PHARMA-B (09939.HK)$ $INNOVENT BIO (01801.HK)$ Today Hong Kong pharmaceutical and biotech stocks fell 2.36%, industry groups in Hong Kong or top 5, kill the biological medicine market valuation, capital is still wary of innovative drug, exploit medicine, corning jerry that is called a fall, but has strong industry leading cinda biology, growth of 4.16% in the pharmaceutical sector in the first, Market money still likes and likes a few big champions.